196 related articles for article (PubMed ID: 27734130)
1. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.
Koren-Michowitz M; Lavi N; Ellis MH; Vannucchi AM; Mesa R; Harrison CN
Ann Hematol; 2017 Jan; 96(1):87-92. PubMed ID: 27734130
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
4. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
6. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.
Ellis MH; Lavi N; Vannucchi A; Harrison C
Thromb Res; 2014 Aug; 134(2):251-4. PubMed ID: 24842684
[TBL] [Abstract][Full Text] [Related]
7. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
Ochiai T; Yasuda H; Araki M; Misawa K; Morishita S; Nudejima M; Hironaka Y; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Eur J Haematol; 2018 Jun; 100(6):544-549. PubMed ID: 29405428
[TBL] [Abstract][Full Text] [Related]
8. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
9. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
11. Triple-Negative Essential Thrombocythemia Complicated by Thrombosis and Acquired von Willebrand Disease in a Young Man.
Kanderi T; Puthenpura M; Shrimanker I; Sapna F; Felter SC
Am J Case Rep; 2020 Aug; 21():e924560. PubMed ID: 32829377
[TBL] [Abstract][Full Text] [Related]
12. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
14. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
[TBL] [Abstract][Full Text] [Related]
15. Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients.
Thom CS; Echevarria E; Osborne AD; Carr L; Rubey KM; Salazar E; Callaway D; Pawlowski T; Devine M; Kleinman S; Witmer C; Flibotte J; Lambert MP
J Thromb Haemost; 2020 Dec; 18(12):3352-3358. PubMed ID: 32979018
[TBL] [Abstract][Full Text] [Related]
16. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
17. Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment.
Scharf RE
Hamostaseologie; 2016 Nov; 36(4):241-260. PubMed ID: 27414763
[TBL] [Abstract][Full Text] [Related]
18. The role of blood component removal in essential and reactive thrombocytosis.
Greist A
Ther Apher; 2002 Feb; 6(1):36-44. PubMed ID: 11886575
[TBL] [Abstract][Full Text] [Related]
19. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study.
Larsson AE; Andréasson B; Holmberg H; Liljeholm M; Själander A
Eur J Haematol; 2023 Jun; 110(6):608-617. PubMed ID: 36725666
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
